VHL human
SIGMA/SRP2084 - recombinant, expressed in insect cells, ≥70% (SDS-PAGE)
Synonym: HRCA1; RCA1; VHL1
Product Type: Chemical
Immunoblotting VHL Cat. No. SRP2084: VHL was separated on SDS-PAGE using 1-3 μg protein (left); and a protein marker (right).
| assay | ≥70% (SDS-PAGE) |
| biological source | human |
| color | clear colorless |
| concentration | 650 μg/mL |
| form | frozen liquid |
| mol wt | ~26 kDa |
| NCBI accession no. | NM_000551   |
| packaging | pkg of 5 μg |
| recombinant | expressed in insect cells |
| shipped in | dry ice |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −70°C |
| UniProt accession no. | P40337 |
| Biochem/physiol Actions: | von Hippel-Lindau (VHL) disease is a hereditary cancer with a predilection for the central nervous system and retina. The von Hippel-Lindau tumor suppressor gene is mutated in families with von Hippel-Lindau disease and encodes a protein (VHL) of 213 amino acids with an acidic pentapeptide motif in the N-terminus. Mutations in the VHL gene result in constitutive expression of many hypoxia-induced genes, at least in part because of increases in the cellular level of hypoxia-inducible transcription factor HIF-1a. VHL protein binds to elongin B, elongin C, and Cul2 to form a stable complex that targets hypoxia inducible factors (HIFs) for degradation and transcriptional regulation. In addition, VHL protein has also been shown to interact with specific protein kinase C isoforms, histone deacetylases and HIF-1 inhibitor (HIF-1). |
| Physical form: | Clear and colorless frozen liquid solution |
| Preparation Note: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥70% (SDS-PAGE) |
| Storage Temp. | −70°C |
| UNSPSC | 12352200 |